Anzeige
Mehr »
Login
Freitag, 24.01.2025 Börsentäglich über 12.000 News von 683 internationalen Medien
Hinter dem nuklearen Ansturm im Silicon Valley: Eine strategische Chance entsteht
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CR1N | ISIN: KYG1996C1006 | Ticker-Symbol:
Branche
Biotechnologie
Aktienmarkt
ASIEN
1-Jahres-Chart
CARSGEN THERAPEUTICS HOLDINGS LTD Chart 1 Jahr
5-Tage-Chart
CARSGEN THERAPEUTICS HOLDINGS LTD 5-Tage-Chart

Aktuelle News zur CARSGEN THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
16.01.HSI Closes Midday at 19,445, Up 159 pts; HSTI Closes Midday at 4,401, Up 37 pts; CHINAHONGQIAO Up over 4%; HSBC HOLDINGS, CARSGEN-B, LAOPU GOLD, PCCW, STELLA HOLDINGS Hit New Highs7
10.01.CARSGEN-B (02171): CHANGE OF ADDRESS OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG AND DATE OF BOARD MEETING-
03.01.CARsgen gets a win for CAR-T in solid tumours-
02.01.CARsgen touts phase 2 stomach cancer win for cell therapy, revs up for China submission-
CARSGEN THERAPEUTICS Aktie jetzt für 0€ handeln
30.12.24CARsgen Therapeutics: CARsgen Announces Positive Topline Results from China GC/GEJ Pivotal Phase II Clinical Trial of Claudin18.2 CAR-T (Satri-cel)88 SHANGHAI, Dec. 30, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for...
► Artikel lesen
30.12.24CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - POSITIVE PIVOTAL PHASE II CLINICAL TRIAL TOPLINE RESULTS FOR SATRICABTAGENE AUTOLEUCEL IN ADVANCED GASTRIC/GASTROESOPHAGEAL ...1
10.12.24CARSGEN-B (02171): TERMS OF REFERENCE FOR THE AUDIT COMMITTEE2
10.12.24CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - UPDATED RESEARCH RESULTS ON ZEVOR-CEL, CT071 AND CT0590 AT ASH 2024 ANNUAL CONGRESS1
18.11.24CARSGEN-B (02171): GRANT OF OPTIONS PURSUANT TO THE POST-IPO SHARE OPTION SCHEME-
01.11.24CARsgen Therapeutics: CARsgen U.S. Clinical Holds Lifted by FDA65SHANGHAI, Oct. 31, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for...
► Artikel lesen
01.11.24CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - LIFT OF THE U.S. CLINICAL HOLDS FOR ZEVORCABTAGENE AUTOLEUCEL, SATRICABTAGENE AUTOLEUCEL AND CT071 BY FDA1
17.10.24CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - TO PRESENT ZEVORCABTAGENE AUTOLEUCEL, CT071 AND CT0590 AT ASH 2024 ANNUAL CONGRESS1
10.10.24China's CARsgen Applies to Resume CAR-T Cell Therapy Trials in US After Passing Reinspection1
09.10.24CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - APPLICATION TO REQUEST LIFTING CLINICAL HOLDS SUBMITTED TO FDA1
09.09.24CARSGEN-B (02171): INTERIM REPORT 20241
29.08.24CARsgen Therapeutics: CARsgen Announces 2024 Interim Results133SHANGHAI, Aug. 29, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies...
► Artikel lesen
28.08.24CARSGEN-B (02171): ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2024-
19.08.24CARsgen Therapeutics: CARsgen Announces Enrollment Completion in China GC/GEJ Pivotal Phase II Clinical Trial of the First-in-class Claudin18.2 CAR T (Satri-cel)98SHANGHAI, Aug. 19, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies...
► Artikel lesen
19.08.24CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - COMPLETION OF ENROLLMENT OF CONFIRMATORY PHASE II CLINICAL TRIAL OF SATRICABTAGENE AUTOLEUCEL IN CHINA1
15.08.24CARSGEN-B (02171): DATE OF BOARD MEETING1
Seite:  Weiter >>
24 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1